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Abstract
Fluid homeostasis, blood pressure and redox balance 
in the kidney are regulated by an intricate interaction 
between local and systemic anti-natriuretic and natriuretic 
systems. Intrarenal dopamine plays a central role on 
this interactive network. By activating specific receptors, 
dopamine promotes sodium excretion and stimulates 
anti-oxidant and anti-inflammatory pathways. Different 
pathological scenarios where renal sodium excretion is 
dysregulated, as in nephrotic syndrome, hypertension and 
renal inflammation, can be associated with impaired action 
of renal dopamine including alteration in biosynthesis, 
dopamine receptor expression and signal transduction. 
Given its properties on the regulation of renal blood flow 
and sodium excretion, exogenous dopamine has been 
postulated as a potential therapeutic strategy to prevent 
renal failure in critically ill patients. The aim of this review 
is to update and discuss on the most recent findings 
about renal dopaminergic system and its role in several 
diseases involving the kidneys and the potential use of 
dopamine as a nephroprotective agent. 
Key words: Dopamine; Hypertension; kidney; Na+, K+-
ATPase; Sodium; Oxidative stress; D1 receptors; D2 
receptors; Renal failure; Edema
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Core tip: Renal dopaminergic system is a local and 
independent natriuretic system necessary to maintain 
the normal balance of sodium and water, blood pressure 
and renal redox steady state. Different findings from 
experimental and clinical studies highlight the participation 
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of renal dopamine in the pathophysiology of renal 
inflammation, hypertension, diabetic nephropathy and 
edema formation. Recent findings from experimental and 
clinical studies allow us to understand the complexity of 
this system as well as its possible contribution for future 
therapeutic strategies to prevent renal diseases. 
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INTRODUCTION
Kidney has all the bioenzymatic machinery necessary 
to possess a local dopaminergic system. Renal 
dopamine production depends on the precursor L-­
dihydroxyphenylalanine and dopa decarboxylase 
activity. Although dopa decarboxylase is present in 
high concentrations in the proximal tubular cells, 
L-­dopa uptake by sodium dependent and independent 
transporters represents the limiting step for intrarenal 
dopamine synthesis[1-­4]. Intrarenal dopamine can leave 
the cell through the apical border by a diffusional process, 
whereas plasma dopamine can be uptaken through the 
basal cell border by a saturable process[5]. The organic 
cation transporters (OCTs and OCTNs) have been 
postulated as potential carriers for dopamine through 
the tubular cells[5-­7]. Finally, dopamine can be eliminated 
with urine flow or degraded by methylation (via catechol-­
O-­methyl transferase or COMT) to 3-­methoxytyramine, 
and by deamination (via monoamine oxidase or MAO) to 
3,4-­dihydroxyphenylacetic acid[8]. 
Several organs and systems are involved in the 
regulation of blood pressure. In particular, the kidney 
plays an essential role in the etiology of hypertension, 
but also represents a target organ vulnerable to hyper-­
tensive tissue damage. Alterations in renal tubule 
transport may be linked to the onset of hypertension 
in which dopamine could play an important role by 
affecting sodium handling on the proximal tubule[9]. 
Dopamine, as a major regulator of proximal tubule salt 
and water reabsorption, exerts its physiological actions 
through two families of receptors located in the tubular 
cell surface: D1-­like receptors (D1 and D5) and D2-­
like receptors (D2, D3 and D4)[10-­14]. Through activation 
of D1-­like receptors, locally produced dopamine acts 
as an autocrine/paracrine natriuretic hormone by 
inhibiting the activity of both apical (e.g., Na+/H+ 
exchange, Cl-­/HCO3-­ exchange and Na+/Pi cotransport) 
and basolateral (e.g., Na+, K+-­ATPase and Na+/HCO3-­ 
cotransport) transporters[15-­17]. The D1-­like receptors, 
coupled to the stimulatory G proteins Gαs and Golf, are 
characterized by their capacity to activate adenylate 
cyclase, while D2-­like receptors, coupled to the inhibitory 
G proteins Gαi and Go, are characterized by their 
capacity to inhibit adenylate cyclase and modulate ion 
channels[18,19]. The classical signaling pathway for D1-­
like receptors leads to activation of adenylate cyclase 
and increases cyclic adenosine 3′,5′-monophosphate 
(cAMP) levels and protein kinase A (PKA) activation. 
PKA may either directly phosphorylate a target protein, 
such as a sodium transporting protein, or initiate a 
cascade of phosphorylation events by phosphorylation 
and activation of dopamine and cAMP-­regulated phos-­
phoprotein DARPP32[1]. D1 receptor can also stimulate 
phospholipase Cβ1 in renal tubules[20]. On the other 
hand, D2-­like receptors can suppress Akt (protein 
kinase B) signaling pathway[21]. Both types of dopamine 
receptors are also linked to mitogen-­activated protein 
kinase activation through different pathways and can 
interact with each other, resulting in new signaling 
pathways. In renal cortical cells the interaction between 
D1 and D2 receptors increases phospholipase C stim-­
ulation[22].
At glomerular level, dopamine increases cAMP in 
mesangial and podocyte cells via D1-­like receptor and 
inhibits angiotensin Ⅱ-­mediated contraction in mesangial 
cells[23,24]. Through this mechanism, dopamine induces 
depolarization of the podocyte that may lead to its 
relaxation[25]. These data suggest that dopamine can 
augment natriuresis and diuresis by increasing directly 
water and sodium filtration at glomerular level. Besides 
these effects on sodium and water homeostasis, it has 
been demonstrated that dopamine could exert anti-­
inflammatory and anti-oxidants properties by activation 
of D1-­like and D2-­like receptors[26-­29]. 
To date, several studies reported that an intact 
dopaminergic system is required to maintain renal hemo-­
dynamic, fluid and electrolyte balance, redox steady 
state and blood pressure within a normal range and to 
antagonize the renin-­angiotensin system[30,31]. In this 
way, alterations in dopamine production and its receptor 
number, function and/or post-translational modification 
are associated with different pathological scenarios 
like oxidative stress, genesis and progression of renal 
dysfunction, edema formation and genetic or essential 
hypertension. In clinical practice, dopamine is used as a 
first line vasoactive agent in patients with hemodynamic 
instability unresponsive to fluid therapy[32]. However, 
despite its diuretic and natriuretic properties, its clinical 
use in patients with renal failure remains controversial.
EFFECTS OF INTRARENAL DOPAMINE 
ON OXIDATIVE STRESS AND RENAL 
INFLAMMATION 
The redox state of cells represents a balance between 
the generation of free radical/highly reactive species 
and the presence of antioxidant mechanisms. Acting as 
cellular messengers, reactive oxygen species (ROS) are 
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implicated in the destruction of invading pathogens. 
Pathological situations involving overproduction of 
free radicals (e.g., atherosclerosis, hypertension, etc.) 
can lead to an increase in oxidative stress status, 
disrupting the normal cellular signaling mechanisms by 
alteration of the normal redox state of cells[33-­36]. 
Oxidative stress and infiltration of inflammatory 
cells in the kidney are involved in the development of 
renal injury and hypertension[37]. Renal tubule cells 
produce both pro-­ and anti-­inflammatory cytokines 
and chemokines, which are secreted across their apical 
and basolateral membranes, and are implicated in 
the development and progression of glomerular and 
tubular injury[38,39].
Several enzymes and receptors are involved in the 
regulation of the redox balance, including nicotinamide 
adenine dinucleotide reduced form (NADPH) oxidase and 
dopamine receptors (D1-­like and D2-­like receptors)[30]. 
Renal dopaminergic system represents a negative 
regulator of ROS. In this sense, D1, D2, and D5 receptors 
can exert antioxidant effects through direct and 
indirect inhibition of pro-­oxidant enzymes, specifically, 
NADPH oxidase, and through stimulation of antioxidant 
enzymes such as superoxide dismutase (SOD) and 
heme-­oxygenase (HO) among others, which can also 
indirectly inhibit NADPH oxidase activity[30,40]. Particularly, 
stimulation of D2 receptors in the kidney increases 
the expression of endogenous anti-­oxidants, such as 
Parkinson protein 7 (PARK7 or DJ-­1), paraoxonase 2, and 
HO-­2, all of which can inhibit NADPH oxidase activity. By 
inhibition of phospholipase D2, the D5 receptor reduces 
NADPH oxidase activity. This receptor subtype also 
increases the expression of another antioxidant enzyme, 
HO-­1. Finally, D1 receptor inhibits NADPH oxidase 
activity via PKA and PKC cross-­talk and stimulates SOD, 
glutathione peroxidase, and glutamyl cysteine transferase 
activities (Figure 1)[30,40].
Additionally, it has been demonstrated that dopamine 
regulates the immune response and the inflammatory 
reaction by inhibiting the release of interferon γ (IFNγ), 
interleukin 2 (IL-­2), and IL-­4 and the lipopolysaccharide-­
stimulated production of IL-­12p40 in immune cells[29,41]. 
Other authors showed that mice with intrarenal do-­
pamine deficiency have increased oxidative stress 
and inflammatory cells infiltration; and that reduction 
in intrarenal dopamine synthesis is associated with 
increased detrimental effects of angiotensin Ⅱ on renal 
injury[42,43].
Experimental studies demonstrated that mice 
lacking D2 receptor (-­/-­) have increased levels of blood 
pressure as well as renal expression of inflammatory 
factors and renal injury[44,45]. To clarify if decreased D2 
receptor function increases the vulnerability to renal 
inflammation, independently of blood pressure, Zhang 
et al[46] carried out experiments with D2 receptor 
(-­/-­) mice, and demonstrated that the treatment with 
apocynin (an inhibitor of NADPH oxidase) normalized 
blood pressure levels and decreased oxidative stress, 
without affecting the expression of inflammatory 
factors. In support of this evidence, it was reported 
that short-­term D2 receptor silencing in one kidney 
(leaving the other kidney intact) in mice, induced the 
overexpression of inflammatory factors and markers 
of renal injury in the treated kidney, without increasing 
blood pressure levels[46]. Altogether, these studies 
indicate that D2 receptor impairment may cause 
renal inflammation as a primary effect, contributing 
to the subsequent development of hypertension. 
Polymorphisms of the human D2 receptor gene may 
be of clinical relevance since reduction in D2 receptor 
expression and function may lead to renal damage and 
oxidative stress[45,46].
Although these evidences indicate that alteration 
of the renal dopaminergic system may be associated 
with increased blood pressure via oxidative stress, 
this seems not to be the only mechanism by which 
impairment of renal dopaminergic system could lead 
to hypertension.
ROLE OF RENAL DOPAMINERGIC 
SYSTEM IN THE PATHOPHYSIOLOGY OF 
HYPERTENSION
Essential hypertension affects 25% of the adult population 
and constitutes a major risk factor for stroke, myocardial 
infarction, and heart and kidney failure[47-­50]. The etiology 
of hypertension is complex and involves both genetic 
and environmental factors[51]. Genome-­wide association 
studies have been able to identify 2% of genetic factors 
believed to influence blood pressure[52-­58]. However, the 
studies were not designed to identify predisposing genes 
engaged in a complex network of gene-­gene and gene-­
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Figure 1  Dopamine receptors and regulation of redox state. Full line: 
Stimulation; Dotted line: Inhibition. D1R: Dopamine receptor subtype 1; D2R: 
Dopamine receptor subtype 2; D5R: Dopamine receptor subtype 5; NADPH: 
Nicotinamide adenine dinucleotide reduced form; SOD: Superoxide dismutase; 
HO-1: Heme oxygenase 1; HO-2: Heme oxygenase 2; PON2: Paraoxonase 2; 
DJ-1: Parkinson protein 7; GP: Glutathione peroxidase; GCT: Glutamyl cysteine 
transferase.
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processes including hypertension. Blood pressure levels 
increase with aging, and alterations in both D1 and 
AT1 receptor functions are closely associated with the 
development of age-­related hypertension[68,73-­75]. Aging 
is a process associated with increase in oxidative stress 
and dysfunction of renal D1 and AT1 receptors[76-­79]. 
Both receptors influence the activity of tubular Na+, K+-­
ATPase and contribute to maintain sodium homeostasis 
and blood pressure[77,79]. It has been reported in 
spontaneously hypertensive and obese Zucker rats an 
increase in oxidative stress and altered renal D1 and AT1 
receptor functions[80-­83]. 
Another possible mechanism involved in the impaired 
natriuretic effect in spontaneously hypertensive rats 
(SHRs) could be related to impaired endothelin B and D3 
receptor interaction[84]. The endothelin B and dopamine 
receptors can interact to regulate renal function and 
blood pressure[85]. It has been demonstrated that 
activation of renal D3 receptor induces natriuresis and 
diuresis, but this effect is reduced in the presence of 
an endothelin B receptor antagonist, demonstrating 
that dopamine effects depends partially on endothelin 
B receptors. Moreover, stimulation of endothelin B 
receptor increases D3 receptor protein expression 
and vice versa in renal proximal tubule from Wistar 
Kyoto rats but not from SHRs[84,86]. Another study 
indicates that D3 receptors physically interact with 
proximal tubule endothelin B receptors and that the 
blunted natriuretic effect of dopamine in SHRs may 
be explained, in part, by abnormal D3/endothelin B 
environment interactions[59]. Many genes have been 
proposed to cause hypertension and more than one 
gene is undoubtedly involved. On the other hand, the 
impairment of renal dopaminergic system functionality 
in hypertension has been extensively studied in patients 
as well in experimental animals, and strong evidences 
indicate that the alteration of this system plays a 
pathophysiological role in the development of different 
types of hypertension[30,60] (Figure 2). Several animal 
experimental models of hypertension exhibit one or 
more defects related to the renal dopaminergic system, 
and vice versa, different models with impairment of 
this system are associated with the development of 
hypertension (Table 1).
The interaction between renal dopamine and an-­
giotensin Ⅱ can take place at receptors level[18]. In this 
way, AT2 and D1 receptors cooperatively oppose the 
vasoconstrictor and antinatriuretic functions elicited by 
angiotensin Ⅱ at AT1 receptor. It has been demonstrated 
that in vivo administration of fenoldopam (a highly 
selective D1-­like receptor agonist) in sodium loaded 
Sprague Dawley rats induces the translocation of AT2 
receptors from intracellular compartment to the apical 
plasma membranes[71]. This effect was confirmed by 
the fact that fenoldopam-­induced natriuretic response 
was completely inhibited by the intrarenal co-­infusion 
of the AT2 receptor antagonist PD123390[72]. Therefore, 
the alterations in D1 receptor-­dependent translocation 
of AT2 receptor must be considered as a contributor 
factor for the initiation and progression of disease 
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Figure 2  Impaired renal dopaminergic system and its association with hypertension. Red full squares and arrows indicate those factors that promote the 
impairment of renal dopamine; blue dotted squares and arrows indicate those factors that enhance renal dopaminergic system. IR: Insulin-resistance; COMT: 
Catechol-O-methyl-transferase; MAO: Monoamine-oxidase: AT1: Angiotensin II receptor subtype 1; AT2: Angiotensin II receptor subtype 2; COX-2: Cyclooxygenase 
type 2; ANP: Atrial natriuretic peptide; NPR-A: Natriuretic peptide receptor type A; LATs: L-aminoacids transporters; OCTs: Organic cationic transporters; GRK4: 
G-protein receptor kinase 4.
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receptor heterodimerization[85].
The interaction between prostanoids and renal 
dopamine on sodium and water excretion must also 
be considered. It has been demonstrated that the 
natriuretic response to dopamine was lower in Dahl 
salt-­sensitive rats but this effect was reversed when 
chromosome 5 was transfered into these rats, leading 
to an increase of the renal expression of CYP4A protein 
and the production of 20-­HETE[87]. Moreover, the 
inhibition of Na+, K+-­ATPase activity by dopamine in 
the proximal tubule may be the result of the synergism 
between 20-­HETE and the D1 signaling pathway[88]. 
In addition, other metabolites of arachidonic acid 
produced in the proximal tubule are epoxyeicosatrienoic 
acids and dihydroxyeicosatrienoic acids. As 20-­HETE, 
epoxyeicosatrienoic acids can also regulate Na+, K+-­
ATPase activity and serve as second messengers for the 
natriuretic effects of dopamine. Since renal production 
of cytochrome P450 metabolites of arachidonic acid is 
altered in hypertension, a lower prostanoid synthesis 
may be involved in the impaired response to dopamine 
in this context[89].
Another protein that could be involved in the path-­
ophysiology of hypertension is the novel amine oxidase, 
renalase[18]. Renalase is synthesized in the kidney 
with high expression in the proximal tubule, and then 
secreted into plasma and urine[19]. Renalase specifically 
degrades catecholamines, including dopamine. Recent 
findings indicate that renalase deficiency is associated 
with increased blood pressure and elevated circulating 
catecholamines[90,91]. Renalase expression depends on 
salt intake, and recombinant renalase exhibits a potent 
and prolonged hypotensive effect on blood pressure 
in Dahl salt-­sensitive rats and rats with chronic kidney 
disease[92,93]. Urinary renalase metabolizes urinary 
catecholamines and it has been hypothesized that it 
might regulate dopamine concentration in the luminal 
fluid. However, the mechanisms of hypertension in 
animals with renalase deficiency and its relationship 
with the renal dopaminergic system are still unclear and 
deserve to be investigated in more detail.
Given its participation on sodium and water exc-­
retion and blood pressure regulation as well as its 
antioxidant properties in the kidney, alteration in renal 
dopaminergic system should also be considered in 
the pathophysiology of other diseases associated with 
Table 1  Renal dopaminergic system impairment in experimental hypertension
Animal experimental model Renal dopaminergic system impairment Principal findings Ref.
Spontaneously hypertensive 
rats 
D1-like receptor function impairment 
caused by a defective coupling of the 
receptor with AC
Increased sodium reabsorption as a mechanism of 
hypertension
Ohbu et al[61]
Dahl salt-sensitive rats D1-like receptor function impairment 
caused by a defective coupling of the 
receptor with AC
Prehypertensive Dahl salt-sensitive rats exhibit a blunted 
natriuretic response to dopamine compared with Dahl salt-
resistant rats
Nishi et al[62]
DOCA salt-sensitive rats Decreased renal dopamine production Renal dopaminergic system is dominantly supressed in this 
model of hypertension
Iimura et al[63]
Dopamine receptor 
knockout mice
Defective D1-D2 like receptor/signal 
transduction 
Impaired D1 and D2-like receptor signal pathway associated 
with development of hypertension
Banday et al[64]
Zeng et al[65]
Albrecht et al[66]
C57BL/6 mice D1-like receptor function impairment 
associated with increased expression of 
GRK4 upon salt loading
Impaired ability to excrete a salt load with a resultant 
increase in blood pressure levels
Escano et al[67]
Mice with selective proximal 
tubule AADC deletion
Deletion of the kidney’s ability to 
generate dopamine is associated with 
unbuffered response to angiotensin II 
that leads to hypertension and decreased 
longevity in mice
Increased expression of tubular sodium transporters, 
decreased natriuresis and diuresis in response to L-Dopa, 
decreased medullary COX-2 expression and urinary 
prostaglandin E2 excretion, increased renin and AT1 receptor 
expression, decreased AT2 and Mas receptor expression, and 
finally salt-sensitive hypertension.
Zhang et al[42]
Old FBN rats Reduction of G-protein coupling in 
response to D1R activation associated 
with exaggerated AT1 receptor activity
Increase of oxidative stress Chugh et al[68]
Renalase knockout mice Alteration of urinary dopamine 
concentration in luminal fluid and 
proximal tubular transport
Impaired sodium excretion with increased blood pressure Desir[18]
3/4 nephrectomized (3/4nx) 
rats
Decrease in urinary levels of dopamine 
and in renal AADC activity 
A reduction in the natriuretic response to volume expansion 
with a time-dependent increase in both systolic and diastolic 
blood pressure
Moreira-
Rodrigues et al[69]
Obese Zucker rats Decrease in D1-like dopamine receptor 
binding sites and diminished activation 
of G proteins 
Overproduction of ROS Hussain et al[70]
GRK4: G protein receptor kinase 4; D1R: Dopamine receptor subtype 1; COX-2: Cyclooxygenase type 2; AT1: Angiotensin II receptor subtype 1; AT2: 
Angiotensin II receptor subtype 2; ROS: Reactive oxygen species; AC: Adenylate cyclase; FBN: Fischer 344 x Brown Norway F1.
Choi MR et al . Renal dopamine: Experimental and clinical evidences
201 May 6, 2015|Volume 4|Issue 2|WJN|www.wjgnet.com
kidney damage such as diabetic nephropathy.
RENAL DOPAMINE, HYPERINSULINEMIA 
AND PATHOPHYSIOLOGY OF DIABETIC 
NEPHROPATHY
Diabetes in cursive is the most prevalent cause of end-­
stage kidney disease and its incidence has increased 
by more than 50% in the last 10 years[94]. Diabetic 
nephropathy is associated with elevated glomerular 
filtration rate, enhanced tubular sodium reabsorption, 
reduced sodium delivery to the macula densa and 
also with progressive glomerular and tubulointerstitial 
injuries[95,96]. Diabetic nephropathy is a major cause 
of mortality in both types diabetes. Adults with type 1 
and 2 diabetes demonstrate insulin resistance, which is 
associated with diabetic nephropathy[97,98]. Experimental 
studies of diabetic nephropathy helped to understand 
the pathophysiological mechanisms underlying the 
disease process and allowed to identify potential 
molecular targets for future pharmacological treatment. 
In this way, it has been demonstrated a decrease 
in endothelial nitric oxide synthase (eNOS) activity 
and renal dopamine production and an increase in 
Nrf-­2, JAK/STAT and mTORC1 signaling as contributor 
factors in the development of diabetic nephropathy[99]. 
Alteration of mechanisms involving dopamine handling 
and signaling by the proximal tubule cells could lead 
to a progressive damage in diabetic nephropathy. In 
addition to the renin angiotensin system, alterations 
of renal cyclooxygenase-­2 (COX-­2) function are also 
involved in renal hemodynamic changes and structural 
abnormalities observed in diabetic nephropathy[100-­102]. 
Previous findings showed that renal dopamine inhibits 
COX-­2 expression in the macula densa, suggesting 
that the impairment of intrarenal dopaminergic system 
observed in diabetes, may contribute to reduce the 
luminal offer of sodium to this area, resulting in an 
elevated macula densa COX-­2 expression[17,103,104] 
(Figure 3). Another experimental study carried out 
in mouse models of type 1 diabetes demonstrated 
that enhanced proximal tubule dopamine levels by 
deletion of COMT-­/-­ gen was associated with substantial 
amelioration of early hyperfiltration, decreased macula 
densa COX-­2 expression, decreased albuminuria 
and glomerulopathy, and inhibition of inflammation 
markers, oxidative stress, and fibrosis[31,99]. Conversely, 
depletion of proximal tubule dopamine levels by 
deletion of dopa decarboxylase gen in diabetic mice 
developed a marked increase in albuminuria as well as 
increment of mesangial expansion, renal macrophage 
infiltration, and renal nitrotyrosine levels[31]. These 
findings contribute to confirm the major role played by 
the intrarenal dopaminergic system on the development 
and progression of kidney injury caused by diabetes 
mellitus.
In renal proximal tubule cells, insulin and dopamine 
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Figure 3  Association between diabetes and renal dopaminergic system in the pathophysiology of diabetic nephropathy. COX-2: Cyclooxygenase-2; GFR: 
Glomerular filtration rate; SNGFR: Single nephron glomerular filtration; eNOS: Endothelial nitric oxide synthase; ROS: Reactive oxygen species.
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counter-­regulate each other by opposing their effects 
on Na+, K+-­ATPase activity[70]. Although insulin has 
been reported to enhance renal proximal tubule uptake 
of L-­dopa in normal fed control rats, this regulatory 
mechanism is absent in cells isolated from animals 
fed with fructose, a model of insulin resistance. In 
addition, the chronic exposure of renal proximal tubule 
cells to insulin causes a reduction in D1 receptor 
abundance and uncoupling from G-­proteins, which 
results in the impairment of the inhibitory effects of 
dopamine on Na+, K+-­ATPase[70,105]. Hyperinsulinemic 
animals and patients with type 2 diabetes present a 
defective renal dopaminergic system[106]. In obese 
Zucker rats, a model of type 2 diabetes or in insulin-
induced hypertension, renal D1 receptors are down-­
regulated and dopamine fails to produce diuresis and 
natriuresis[70]. Moreover, when these animals were 
treated with an insulin sensitizer (rosiglitazone), plasma 
insulin levels decreased and D1 receptor function were 
restored[107,108] (Figure 4). Based on these evidences, 
it is possible that the regulatory mechanisms of the 
renal dopaminergic system are impaired in diabetic 
nephropathy due to insulin resistance. 
Previous studies have shown that in both type 1 
and type 2 diabetes, expression of renal D1 receptor 
gene was reduced above 50% through a down-­
regulation mechanism that involves the extracellular 
cAMP-­adenosine signaling pathway[70,109]. An increase 
in intrarenal dopamine synthesis and the subsequent 
stimulation of vascular D1 receptors appear to prevent 
early glomerular hyperfiltration in diabetic rats[110]. 
Conversely to the D1 like receptors, selective antagonism 
of D2 like receptors was demonstrated to reverse 
glomerular hyperfiltration induced by experimental 
diabetic hyperglycemia[111]. Additionally, activation of 
the D3 receptor in rats caused diuresis, natriuresis 
and increased glomerular filtration[112]. To demonstrate 
the renoprotective effect of a D3 receptor antagonist 
(A-­437203), hypertensive type 2 diabetic (SHR/
N-­cp) rats were used to evaluate the renal effects 
of D3 antagonism on glomerulosclerosis damage 
index, glomerular volume, desmin expression as 
marker of podocyte damage, and urinary albumin 
excretion[113]. The results of this study suggest that D3 
receptor antagonism has a beneficial effect on renal 
morphology and albuminuria, which is comparable in 
magnitude to that of angiotensin-­converting enzyme 
inhibitor treatment as the gold standard[113].
Despite its role in the pathophysiology of diabetic 
nephropathy, the potential clinical use of dopamine in 
this context is still matter of basic research. Nonetheless, 
the therapeutic use of dopamine is restricted to its dose-­
dependent actions on the cardiovascular system.
DOPAMINE AS NEPHROPROTECTIVE 
AGENT? EXPERIMENTAL AND CLINICAL 
EVIDENCES IN RENAL DYSFUNCTION 
Dopamine represents an essential drug in intensive 
care units and is still used as a first line vasopressor 
agent especially in hypotensive adult patients refractory 
to fluid resuscitation[32]. Because of its interaction with 
different catecholamine receptors, the pharmacological 
profile of dopamine is dose dependent[114]. At low 
doses (0.3-­5 µg/kg per minute), dopamine stimulates 
D1 and D2 receptors inducing natriuresis, diuresis 
and enhances renal blood flow by renal vasodilation. 
At higher doses, when adrenergic stimulation pre-­
vails, dopamine increases renal blood flow through 
stimulation of cardiac output[32,114,115]. In healthy adult 
volunteers, the administration of a low dose dopamine 
increases renal blood flow and induces natriuresis and 
diuresis[116,117]. For these reasons, a low-­dose dopamine 
represents a therapeutic option to limit or prevent 
renal failure in critically ill patients by increasing renal 
blood flow[118]. Although a low dose dopamine appears 
to be able to increase urinary output in critically ill adult 
patients at risk of renal failure, a high number of clinical 
studies indicate that the administration of a low dose 
dopamine might not be able to exert any protective 
effect to prevent the onset or improve the course of an 
established acute renal failure, but on the contrary, its 
use may increase its risk[32,114,119-­122]. Taken all together, 
the nephroprotective action of a low dose dopamine in 
critical ill patients remains to date controversial (Table 2).
Although these evidences attempt to the clinical use 
of dopamine, some other findings support the clinical 
benefit of its use in different scenarios like cardio-­
renal syndrome, cardiopulmonary bypass and acute 
decompensated heart failure under treatment with atrial 
natriuretic peptide (ANP)[119,128,129]. Renal dysfunction is 
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Figure 4  Association between insulin resistance and impairment of renal 
dopaminergic system. Full lines: Stimulation; stripped lines: Inhibition.
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one of the most important co-­morbidities in heart failure, 
being a potent predictor of cardiovascular complications 
and mortality[130]. This relationship is commonly termed 
cardio-­renal syndrome, where both, cardiac and renal 
dysfunctions, share similar pathophysiology such as 
activation of the renin-­angiotensin-­aldosterone and 
sympathetic nervous systems, imbalance between nitric 
oxide and reactive oxygen species, and inflammation[131]. 
Clinical guidelines recommend the treatment of heart 
failure or renal failure separately without consensus about 
how managing patients with cardio-­renal syndromes[129]. 
Its specific treatment points out to ameliorate decreased 
urine output and glomerular filtration rate, increased 
serum creatinine, and to prevent weight loss[132]. Recent 
studies in this clinical setting have focused on newer 
therapies, including renal protective dopamine[124,125,129] 
(Table 2). 
Acute kidney injury after cardiac operations 
with cardiopulmonary bypass is a life-­threatening 
complication, with a reported incidence of up to 
36%[133]. To prevent this situation diuretics have been 
the mainstay to promote renal function and urine 
flow after pediatric cardiopulmonary bypass[134,135]. 
Fenoldopam mesylate is a short-­acting D1 agonist that 
Table 2  Clinical studies providing evidence against/in support of clinical use of low dose dopamine
Study design Results Ref.
Against clinical use of 
low dose dopamine
The Australian and New 
Zealand Intensive Care Society 
(ANZICS): multicenter, 
randomized, double-blind, 
placebo-controlled
324 patients with at least two criteria for the systemic inflammatory 
response syndrome and clinical evidence of early renal dysfunction: 
continuous intravenous infusion of low-dose dopamine (2 µg/kg 
per minute) did not attenuate the peak serum creatinine compared 
with placebo. There was no statistical difference in mortality 
between dopamine and placebo arms
Bellomo et al[119]
Meta-analysis study: 17 studies 
were randomized clinical trials (n 
= 854)
Low dose dopamine administration did not prevent mortality or 
the onset of acute renal failure, or the need for haemodialysis in 
clinically ill patients
Kellum and M 
Decker[120]
Meta-analysis study: 15 
randomized controlled studies
Dopamine administration did not present beneficial results in terms 
of serum creatinine changes and incidence of acute renal failure in 
clinically ill patients
Marik[121]
Sepsis Occurrence in Acutely 
Ill Patients (SOAP): Cohort, 
multiple-center, observational 
study
Dopamine administration in shock patients, compared to patients 
who did not receive it, was associated with 20% increase in ICU 
and hospital mortality rates
Sakr et al[122]
Renal Optimization Strategies 
Evaluation (ROSE) study: 
multicenter, double-blind, 
placebo-controlled randomized 
clinical trial
Low dose dopamine (2 µg/kg per minute) did not enhance 
decongestion or improved renal function when added to diuretic 
therapy in 360 patients with acute heart failure and renal 
dysfunction
Chen et al[123]
In support of clinical 
use of low dose 
dopamine 
Dopamine in Acute 
Decompensated Heart Failure 
(DAD-HF) Trial: randomized 
clinical trial
The addition of low-dose dopamine (5 μg/kg per minute) to low-
dose furosemide (5 mg/h) was associated with improvement in 
renal function profile and potassium homeostasis at 24 h and it 
was equally effective as high-dose furosemide (20 mg/h) alone 
on subjective perception of dyspnoea in 60 patients with acute 
decompensated heart failure
Giamouzis et al[124]
Retrospective clinical study Continuous infusion of furosemide in addition to low-dose 
dopamine compared to intermittent boluses of furosemide was 
less nephrotoxic and carried a lower readmission rate at 30 d in 116 
patients with acute decompensated heart failure
Aziz et al[125]
A prospective single-center 
randomized double-blind 
placebo controlled trial
The treatment with high-dose fenoldopam at 1 µg/kg per minute 
(short-acting D1 agonist) during cardiopulmonary bypass in 80 
pediatric patients undergoing cardiac surgery for congenital heart 
disease significantly decreased urinary biomarkers of acute kidney 
injury (urinary neutrophil gelatinase-associated lipocaline and 
cystatin C levels) and also reduced the incidence of acute kidney 
injury in the postoperative period and the use of diuretics and 
vasodilators
Ricci et al[126]
Clinical case finding Low doses of ANP (0.0125 µg/kg per minute) with low dose 
dopamine (1.0 µg/kg per minute) in acute decompensated heart 
failure increased urine output, decreased heart rate, improved 
congestion with a reduced brain natriuretic peptide level, 
reduced serum creatinine and the levels of urinary liver-type fatty 
acid binding protein -a novel reno-tubular stress marker- and 
8-hydroxydeoxyguanosine -an oxidative stress marker
Kamiya[127]
Prospective randomized clinical 
study 
Low dose dopamine infusion reduces renal tubular injury 
following cardiopulmonary bypass in 48 patients with normal or 
near normal baseline renal function
Sumeray et al[128]
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appears to improve renal function in clinical situations 
of reduced blood flow by enhancing renal blood 
flow[126,136]. Then, co-­administration of both agents could 
be a reasonable therapeutic strategy to preserve renal 
function in this context (Table 2).
A primary therapeutic goal for acute heart failure 
is to achieve decongestion to relief symptoms without 
inducing renal dysfunction[137,138]. However, adult patients 
with acute heart failure and moderate or severe renal 
dysfunction are at risk for inadequate decongestion and 
enhanced renal dysfunction, both condition associated 
with worse prognosis[139]. Renal adjuvant therapies like 
dopamine could enhance decongestion and preserve 
renal function during treatment of acute heart failure. In 
this setting, combined therapy with ANP and dopamine 
might be useful to improve the management of acute 
decompensated heart failure without renal injury in 
patients who do not respond to ANP alone[127]. This 
beneficial interaction between both agents could 
be related to previous experimental findings that 
demonstrated that ANP stimulates dopamine uptake 
by tubular cells, reduces its catabolism and diminishes 
the turnover[140,141]. These effects may favor renal 
biodisponibility of dopamine in tubular cells and enhance 
overinhibition of renal Na+, K+-­ATPase activity[141]. 
Nonetheless, future prospective studies are needed to 
affirm this suggestion (Table 2).
As it has been demonstrated in patients with 
heart failure, the interaction between two natriuretic 
hormones, such as ANP and dopamine, can also be 
present in other situations with increased extracellular 
fluid, such as nephrotic syndrome.
RENAL DOPAMINE IN THE PATHOGEN-
ESIS OF EDEMA FORMATION
Nephrotic syndrome exhibits increased proteinuria and 
enhanced sodium retention that contribute to edema 
and ascites formation[142]. Although reduced plasma 
volume and serum albumin concentration contribute 
to sodium retention in nephrotic syndrome, a primary 
intrarenal sodium handling abnormality could also 
be implicated in this clinical scenario[143]. In this 
way, experiments carried out in rats with puromycin 
aminonucleoside (PAN) induced nephrotic syndrome 
showed a blunted activity of the renal dopaminergic 
system evidenced by decreased urine dopamine, 
decreased availability of D1 receptor in renal proximal 
tubules and reduced dopa decarboxylase activity[144]. 
These findings were associated with an increase in Na+, 
K+-­ATPase activity in renal proximal tubules[144]. On 
the other hand, renal dopamine and ANP are known 
to interact with each other in order to regulate sodium 
homeostasis[145]. The complex interaction between 
these two natriuretic systems is evidenced by the fact 
that ANP stimulates proximal tubular dopamine uptake 
through natriuretic peptide receptor type A (NPR-­A), 
guanylate cyclase stimulation and protein kinase G 
(PKG) activation[4]. ANP also recruits silent D1 receptor 
from the interior of the renal tubular cells towards the 
plasma membrane where they become functionally 
active[146]. A recent work of Fernandes Cerqueira 
et al[147] demonstrated in rats with PAN-­nephrotic 
syndrome that the increase of natriuresis and urinary 
cGMP excretion evoked by an acute volume expansion 
were blunted, despite the increased levels of circulating 
ANP, suggesting the unresponsiveness to ANP in this 
pathology. Treatment with a phosphodiesterase type 
5 inhibitor (zaprinast) restored the excretion of cGMP 
and the natriuresis to similar levels of control rats, and 
increased the expression of D1 receptors in tubular 
cells[147]. This evidence indicates that D1 receptors are 
involved in ANP unresponsiveness observed in PAN-­
nephrotic syndrome, where the alteration of renal 
dopaminergic system represents a contributor factor 
for the edema and ascites formation (Figure 5).
Beyond its renal actions, dopamine effects on fluid 
homeostasis can also be exerted in other tissues. In 
this way, recent findings support a possible use of 
dopamine in edema resolution of pulmonary path-­
ologies[148,149]. Acute lung injury and its severe form, 
the acute respiratory distress syndrome are prevalent 
causes of morbidity and mortality[150]. The outcome 
of patients with acute hypoxemic respiratory failure 
improves when lung epithelial function is restored and 
pulmonary edema resolves[151,152]. Pulmonary edema is 
cleared from the alveoli by active sodium transport, in 
which sodium enters into the cell via apical amiloride-­
sensitive sodium channels and pumped out from the 
cell via the basolaterally located Na+, K+-­ATPase. Water 
follows the sodium gradients, resulting in alveolar fluid 
reabsorption[153]. Although dopamine inhibits Na+, K+-­
ATPase in the kidney and promotes natriuresis and 
diuresis, in alveolar cells dopamine increases, in a 
dose-­dependent manner, lung edema clearance in rats 
by 40%-­70% above the control clearance levels[154-­156]. 
Experimental studies using models of lung injury have 
demonstrated that alveolar fluid clearance is impaired 
in parallel with decreased Na+, K+-­ATPase function. In 
these lung injury models, dopamine (10-­5 M) instilled 
into airspace increased alveolar fluid reabsorption by 
translocating preformed Na+, K+-­ATPase pumps from 
intracellular pools (i.e., late endosomal compartment) 
to the cell plasma membrane in alveolar epithelial-­
type Ⅱ cells[150,157,158]. This effect is produced through 
short-­term and long-­term fashion mechanisms. The 
short-­term mechanism depends on the activation of 
D1 receptors since fenoldopam reproduces dopamine 
actions, meanwhile the long-­term mechanism implies 
D2 receptors[159,160]. Accumulation of protein-­rich 
alveolar edema fluid in acute lung injury is the result 
of an increased microvascular permeability[161-­164]. 
Many experimental and human studies support the 
hypothesis that vascular endothelial growth factor 
(VEGF) plays a critical role in shaping the vascular 
barrier function in acute lung injury[165-­169]. Although, D1 
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and D2 receptors are implicated in the synthesis and 
trafficking of Na+, K+-­ATPase, the D2 receptor is also 
implicated in the regulation of VEGF-­induced vascular 
permeability as well as angiogenesis[159,160,170-­172]. This 
was confirmed by the fact that a D2 receptor agonist 
failed to reduce pulmonary edema in D2 receptor 
(-­/-­) mice, suggesting that dopamine acts through 
D2 receptor to inhibit pulmonary edema-­associated 
vascular permeability, which is mediated through 
VEGF-­VEGFR2 signaling and conveys protective 
effects in an acute lung injury model[148]. Although 
D1 and D2 receptors subtypes seem to be beneficial 
to reduce edema formation, D3 receptor appears 
to exert an opposite effect. Several clinical findings 
reported that pramipexole, a potent non ergoline 
agent with high affinity to D3 receptors and used for 
Parkinson’s disease, restless legs syndrome, resistant 
depression and bipolar depression, is associated with 
the development of pedal and chronic lower limb 
edema (with a frequency that ranges from 5% to 
22.5%)[173-­176]. This adverse effect disappears after 
the discontinuation of the drug[173-­176]. Since dopamine 
is an important regulator of the sympathetic nervous 
system, aldosterone secretion, as well as adenosine 
triphosphate-­mediated sodium/potassium channels, 
the peripheral effects of pramipexole at these levels 
could have a role[177,178]. However the relationship 
between D3 receptor agonism and edema formation 
remains unclear.
FUTURE PERSPECTIVES
An intact renal dopaminergic tonus is required for the 
maintenance of sodium homeostasis and normal blood 
pressure. By its anti-oxidative and anti-inflammatory 
properties, intrarenal dopamine plays a major role 
as a nephroprotective agent to prevent or ameliorate 
renal dysfunction. Oxidative stress or hyperinsulinemic 
states may decrease the number of functional dopa-­
minergic receptors in the proximal tubules. In this 
way, it is worthwhile to test the effect of antioxidant 
drugs to enhance or restore the biodisponibility of 
these receptors. A recent observation that dopamine 
receptors availability in the plasma membrane may be 
regulated by other hormones, like ANP, could open up 
a possible therapeutic approach[179]. 
It has been emphasized the importance of endo-­
genous dopamine and renal D1 receptor on the regulation 
of sodium and body fluid homeostasis. Although there is 
evidence that a defective renal dopaminergic system 
contributes to the development and maintenance of 
hypertension, it is still not clear what triggering factors 
cause the selective defects in the renal dopaminergic 
system. Some of these triggering factors could be 
an excess of sodium intake that could lead to an 
activation of intrarenal angiotensin Ⅱ and increase in 
ROS, an increase in carbohydrate intake and a high fat 
diet, both factors that promotes an insulin resistance 
state. Furthermore, the renal dopaminergic system is 
sensitized by a high salt intake and volume expansion, 
which opens the question about how intrarenal sodium 
sensors may influence on renal dopamine bioavailability. 
This approach may lead to the development of 
new pharmacological strategies in conditions of salt 
retention and hypertension. Moreover, identification of 
abnormalities in different steps of crucial importance for 
the regulation of the renal dopaminergic tonus should 
provide additional molecular biological tools for the early 
diagnosis and treatment of pre-­hypertensive patients. 
The fact that dopamine exerts nonselective actions 
upon multiple dopaminergic and adrenergic receptors 
must be considered, and this, can limit its therapeutic 
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use in renal diseases. The potential therapeutic use of 
exogenous dopamine and D1-­like receptor agonists is 
limited to special conditions like critical ill patients who are 
at risk of kidney failure. However, given the controversial 
results from clinical studies the use of dopamine in this 
context must be examined more closely.
At last, further clinical studies must be carried out to 
confirm the participation of renal dopaminergic system 
in pathological contexts involving impaired sodium 
excretion as nephrotic syndrome or insulin resistance 
states.
CONCLUSION
Intrarenal dopamine represents a local natriuretic 
system with beneficial actions on blood pressure, 
oxidative stress and inflammation. Dopamine secreted 
into the tubular lumen acts via D1-­like and D2-­like 
receptors in an autocrine/paracrine manner to inhibit 
different tubular ion transporters and to regulate 
the production of reactive oxygen species and 
the inflammatory response. These renoprotective 
effects can be affected by situations that impair its 
integrity and functionality. The comprehension of the 
mechanisms by which renal dopaminergic system 
is involved in the pathogenesis and development 
of renal diseases may contribute to improve the 
diagnosis, evolution, prognosis and treatment of renal 
pathologies.
ACKNOWLEDGMENTS
We would like to thank Dr. Silvana L Della Penna, for 
her assistance in improving the manuscript writing. 
REFERENCES
1 Silva E, Gomes P, Soares-da-Silva P. Increases in transepithelial 
vectorial Na+ transport facilitates Na+-dependent L-DOPA transport 
in renal OK cells. Life Sci 2006; 79: 723-729 [PMID: 16600308 
DOI: 10.1016/j.lfs.2006.02.018]
2 Bröer A, Klingel K, Kowalczuk S, Rasko JE, Cavanaugh J, Bröer 
S. Molecular cloning of mouse amino acid transport system B0, a 
neutral amino acid transporter related to Hartnup disorder. J Biol 
Chem 2004; 279: 24467-24476 [PMID: 15044460 DOI: 10.1074/
jbc.M400904200]
3 Pinho MJ, Serrão MP, Gomes P, Hopfer U, Jose PA, Soares-da-
Silva P. Over-expression of renal LAT1 and LAT2 and enhanced 
L-DOPA uptake in SHR immortalized renal proximal tubular cells. 
Kidney Int 2004; 66: 216-226 [PMID: 15200428 DOI: 10.1111/
j.1523-1755.2004.00722.x]
4 Correa AH, Choi MR, Gironacci M, Valera MS, Fernández 
BE. Signaling pathways involved in atrial natriuretic factor 
and dopamine regulation of renal Na+, K+ -ATPase activity. 
Regul Pept 2007; 138: 26-31 [PMID: 17005263 DOI: 10.1016/
j.regpep.2006.08.001]
5 Koepsell H, Lips K, Volk C. Polyspecific organic cation 
transporters: structure, function, physiological roles, and 
biopharmaceutical implications. Pharm Res 2007; 24: 1227-1251 
[PMID: 17473959 DOI: 10.1007/s11095-007-9254-z]
6 Wright SH, Dantzler WH. Molecular and cellular physiology of 
renal organic cation and anion transport. Physiol Rev 2004; 84: 
987-1049 [PMID: 15269342 DOI: 10.1152/physrev.00040.2003]
7 Jonker JW, Schinkel AH. Pharmacological and physiological 
functions of the polyspecific organic cation transporters: OCT1, 2, 
and 3 (SLC22A1-3). J Pharmacol Exp Ther 2004; 308: 2-9 [PMID: 
14576340 DOI: 10.1124/jpet.103.053298]
8 Armando I, Konkalmatt P, Felder RA, Jose PA. The renal 
dopaminergic system: novel diagnostic and therapeutic approaches 
in hypertension and kidney disease. Transl Res 2014 [PMID: 
25134060 DOI: 10.1016/j.trsl.2014.07.006]
9 Horita S, Seki G, Yamada H, Suzuki M, Koike K, Fujita T. Roles of 
renal proximal tubule transport in the pathogenesis of hypertension. 
Curr Hypertens Rev 2013; 9: 148-155 [PMID: 23971696]
10 Sanada H, Xu J, Watanabe H, Jose PA, Felder RA. Differential 
expression and regulation of dopamine-1 (D-1) and dopamine-5 
(D-5) receptor function in human kidney. Am J Hypertens 2000; 13: 
156
11 Carey RM. The intrarenal renin-angiotensin and dopaminergic 
systems: control of renal sodium excretion and blood pressure. 
Hypertension 2013; 61: 673-680 [PMID: 23407646 DOI: 10.1161/
HYPERTENSIONAHA.111.00241]
12 Beaulieu JM, Gainetdinov RR. The physiology, signaling, and 
pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 
182-217 [PMID: 21303898 DOI: 10.1124/pr.110.002642]
13 Hussain T, Lokhandwala MF. Renal dopamine receptors and 
hypertension. Exp Biol Med (Maywood) 2003; 228: 134-142 [PMID: 
12563019]
14 Zeng C, Sanada H, Watanabe H, Eisner GM, Felder RA, Jose PA. 
Functional genomics of the dopaminergic system in hypertension. 
Physiol Genomics 2004; 19: 233-246 [PMID: 15548830 DOI: 
101152/physiolgenomics.00127.2004]
15 Pedrosa R, Jose PA, Soares-da-Silva P. Defective D1-like receptor-
mediated inhibition of the Cl-/HCO3- exchanger in immortalized 
SHR proximal tubular epithelial cells. Am J Physiol Renal Physiol 
2004; 286: F1120-F1126 [PMID: 14970001 DOI: 10.1152/
ajprenal.00433.2003]
16 Carey RM. Theodore Cooper Lecture: Renal dopamine system: 
paracrine regulator of sodium homeostasis and blood pressure. 
Hypertension 2001; 38: 297-302 [PMID: 11566894 DOI: 10.1161/
hy0901.096422]
17 Zhang MZ, Yao B, Fang X, Wang S, Smith JP, Harris RC. 
Intrarenal dopaminergic system regulates renin expression. 
Hypertension 2009; 53: 564-570 [PMID: 19139376 DOI: 10.1161/
HYPERTENSIONAHA.108.127035]
18 Desir GV. Role of renalase in the regulation of blood pressure and 
the renal dopamine system. Curr Opin Nephrol Hypertens 2011; 20: 
31-36 [PMID: 21099685 DOI: 10.1097/MNH.0b013e3283412721]
19 Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y, Desir GV. 
Catecholamines regulate the activity, secretion, and synthesis of 
renalase. Circulation 2008; 117: 1277-1282 [PMID: 18299506 DOI: 
10.1161/CIRCULATIONAHA.107.732032]
20 Yu PY, Asico LD, Eisner GM, Jose PA. Differential regulation of 
renal phospholipase C isoforms by catecholamines. J Clin Invest 
1995; 95: 304-308 [PMID: 7814630]
21 Souza BR, Romano-Silva MA, Tropepe V. Dopamine D2 
receptor activity modulates Akt signaling and alters GABAergic 
neuron development and motor behavior in zebrafish larvae. J 
Neurosci 2011; 31: 5512-5525 [PMID: 21471388 DOI: 10.1523/
JNEUROSCI.5548-10.2011]
22 Pollack A. Coactivation of D1 and D2 dopamine receptors: in 
marriage, a case of his, hers, and theirs. Sci STKE 2004; 2004: pe50 
[PMID: 15494560]
23 Bek M, Fischer KG, Greiber S, Hupfer C, Mundel P, Pavenstädt H. 
Dopamine depolarizes podocytes via a D1-like receptor. Nephrol 
Dial Transplant 1999; 14: 581-587 [PMID: 10193803]
24 Barnett R, Singhal PC, Scharschmidt LA, Schlondorff D. 
Dopamine attenuates the contractile response to angiotensin II in 
isolated rat glomeruli and cultured mesangial cells. Circ Res 1986; 
59: 529-533 [PMID: 3467880]
25 Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular 
podocyte. Physiol Rev 2003; 83: 253-307 [PMID: 12506131]
26 Yang Z, Asico LD, Yu P, Wang Z, Jones JE, Escano CS, Wang 
Choi MR et al . Renal dopamine: Experimental and clinical evidences
207 May 6, 2015|Volume 4|Issue 2|WJN|www.wjgnet.com
X, Quinn MT, Sibley DR, Romero GG, Felder RA, Jose PA. D5 
dopamine receptor regulation of reactive oxygen species production, 
NADPH oxidase, and blood pressure. Am J Physiol Regul Integr 
Comp Physiol 2006; 290: R96-R104 [PMID: 16352863 DOI: 
10.1152/ajpregu.00434.2005]
27 Yu P, Han W, Villar VA, Li H, Arnaldo FB, Concepcion GP, 
Felder RA, Quinn MT, Jose PA. Dopamine D1 receptor-mediated 
inhibition of NADPH oxidase activity in human kidney cells occurs 
via protein kinase A-protein kinase C cross talk. Free Radic Biol 
Med 2011; 50: 832-840 [PMID: 21193028 DOI: 10.1016/j.freeradbi
omed.2010.12.027]
28 Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara 
N, Tanaka S, Katsuki I, Matsushita S, Tanaka Y. Dopamine 
induces IL-6-dependent IL-17 production via D1-like receptor on 
CD4 naive T cells and D1-like receptor antagonist SCH-23390 
inhibits cartilage destruction in a human rheumatoid arthritis/SCID 
mouse chimera model. J Immunol 2011; 186: 3745-3752 [PMID: 
21307293 DOI: 10.4049/jimmunol.1002475]
29 Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, 
Bhattacharya D, Dasgupta PS. Dopamine inhibits cytokine release 
and expression of tyrosine kinases, Lck and Fyn in activated T cells. 
Int Immunopharmacol 2003; 3: 1019-1026 [PMID: 12810359 DOI: 
10.1016/S1567-5769(03)00100-0]
30 Cuevas S, Villar VA, Jose PA, Armando I. Renal dopamine 
receptors, oxidative stress, and hypertension. Int J Mol Sci 2013; 
14: 17553-17572 [PMID: 23985827 DOI: 10.3390/ijms140917553]
31 Zhang MZ, Yao B, Yang S, Yang H, Wang S, Fan X, Yin H, 
Fogo AB, Moeckel GW, Harris RC. Intrarenal dopamine inhibits 
progression of diabetic nephropathy. Diabetes 2012; 61: 2575-2584 
[PMID: 22688335 DOI: 10.2337/db12-0046]
32 Marinosci GZ, De Robertis E, De Benedictis G, Piazza O. 
Dopamine Use in Intensive Care: Are We Ready to Turn it Down? 
Transl Med UniSa 2012; 4: 90-94 [PMID: 23905068]
33 Yu P, Han W, Villar VA, Yang Y, Lu Q, Lee H, Li F, Quinn MT, 
Gildea JJ, Felder RA, Jose PA. Unique role of NADPH oxidase 
5 in oxidative stress in human renal proximal tubule cells. 
Redox Biol 2014; 2: 570-579 [PMID: 24688893 DOI: 10.1016/
j.redox.2014.01.020]
34 Bretón-Romero R, Lamas S. Hydrogen peroxide signaling 
mediator in the activation of p38 MAPK in vascular endothelial 
cells. Methods Enzymol 2013; 528: 49-59 [PMID: 23849858 DOI: 
10.1016/B978-0-12-405881-1.00003-3]
35 Chung HS, Wang SB, Venkatraman V, Murray CI, Van Eyk JE. 
Cysteine oxidative posttranslational modifications: emerging 
regulation in the cardiovascular system. Circ Res 2013; 112: 382-392 
[PMID: 23329793 DOI: 10.1161/CIRCRESAHA.112.268680]
36 Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative 
stress-activated signaling pathways mediators of insulin resistance 
and beta-cell dysfunction? Diabetes 2003; 52: 1-8 [PMID: 
12502486 DOI: 10.2337/diabetes.52.1.1]
37 Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, 
Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and 
hypertension. Hypertension 2011; 57: 132-140 [PMID: 21149826 
DOI: 10.1161/HYPERTENSIONAHA.110.163576]
38 Segerer S, Schlöndorff D. Role of chemokines for the localization 
of leukocyte subsets in the kidney. Semin Nephrol 2007; 27: 260-274 
[PMID: 17533005 DOI: 10.1016/j.semnephrol.2007.02.003]
39 Wang Y, Tay YC, Harris DC. Proximal tubule cells stimulated 
by lipopolysaccharide inhibit macrophage activation. Kidney 
Int 2004; 66: 655-662 [PMID: 15253719 DOI: 10.1111/
j.1523-1755.2004.00786.x]
40 Yang Y, Zhang Y, Cuevas S, Villar VA, Escano C, D Asico L, Yu 
P, Grandy DK, Felder RA, Armando I, Jose PA. Paraoxonase 2 
decreases renal reactive oxygen species production, lowers blood 
pressure, and mediates dopamine D2 receptor-induced inhibition of 
NADPH oxidase. Free Radic Biol Med 2012; 53: 437-446 [PMID: 
22634053 DOI: 10.1016/j.freeradbiomed.2012.05.015]
41 Haskó G ,  Szabó C, Németh ZH, Deitch EA. Dopamine 
suppresses IL-12 p40 production by lipopolysaccharide-stimulated 
macrophages via a beta-adrenoceptor-mediated mechanism. J 
Neuroimmunol 2002; 122: 34-39 [PMID: 11777541 DOI: 10.1016/
S0165-5728(01)00459-3]
42 Zhang MZ, Yao B, Wang S, Fan X, Wu G, Yang H, Yin H, Yang S, 
Harris RC. Intrarenal dopamine deficiency leads to hypertension and 
decreased longevity in mice. J Clin Invest 2011; 121: 2845-2854 
[PMID: 21701066 DOI: 10.1172/JCI57324]
43 Yang S, Yao B, Zhou Y, Yin H, Zhang MZ, Harris RC. Intrarenal 
dopamine modulates progressive angiotensin II-mediated renal 
injury. Am J Physiol Renal Physiol 2012; 302: F742-F749 [PMID: 
22169008 DOI: 10.1152/ajprenal.00583.2011]
44 Li XX, Bek M, Asico LD, Yang Z, Grandy DK, Goldstein DS, 
Rubinstein M, Eisner GM, Jose PA. Adrenergic and endothelin 
B receptor-dependent hypertension in dopamine receptor type-2 
knockout mice. Hypertension 2001; 38: 303-308 [PMID: 11566895 
DOI: 10.1161/01.HYP.38.3.303]
45 Armando I, Wang X, Villar VA, Jones JE, Asico LD, Escano C, Jose 
PA. Reactive oxygen species-dependent hypertension in dopamine 
D2 receptor-deficient mice. Hypertension 2007; 49: 672-678 [PMID: 
17190875 DOI: 10.1161/01.HYP.0000254486.00883.3d]
46 Zhang Y, Cuevas S, Asico LD, Escano C, Yang Y, Pascua AM, 
Wang X, Jones JE, Grandy D, Eisner G, Jose PA, Armando I. 
Deficient dopamine D2 receptor function causes renal inflammation 
independently of high blood pressure. PLoS One 2012; 7: e38745 
[PMID: 22719934 DOI: 10.1371/journal.pone.0038745]
47 Ruilope L, Kjeldsen SE, de la Sierra A, Mancia G, Ruggenenti P, 
Stergiou GS, Bakris GL, Giles TD. The kidney and cardiovascular 
risk--implications for management: a consensus statement from the 
European Society of Hypertension. Blood Press 2007; 16: 72-79 
[PMID: 17612904 DOI: 10.1080/08037050701338985]
48 Erdine S, Aran SN. Current status of hypertension control 
around the world. Clin Exp Hypertens 2004; 26: 731-738 [PMID: 
15702628]
49 Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, 
and control of hypertension in the United States, 1988–2000. JAMA 
2003; 290: 199-206 [PMID: 12851274]
50 Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. 
Links between dietary salt intake, renal salt handling, blood 
pressure, and cardiovascular diseases. Physiol Rev 2005; 85: 
679-715 [PMID: 15788708 DOI: 10.1152/physrev.00056.2003]
51 Zeng C, Villar VA, Yu P, Zhou L, Jose PA. Reactive oxygen species 
and dopamine receptor function in essential hypertension. Clin Exp 
Hypertens 2009; 31: 156-178 [PMID: 19330604 DOI: 10.1080/106
41960802621283]
52 Harrap SB. Blood pressure genetics: time to focus. J Am Soc 
Hypertens 2009; 3: 231-237 [PMID: 20409965 DOI: 10.1016/
j.jash.2009.06.001]
53 Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, Huang H, 
Zhou J, Lashley K, Chen Y, Christman M, Rotimi C. A genome-
wide association study of hypertension and blood pressure in 
African Americans. PLoS Genet 2009; 5: e1000564 [PMID: 
19609347 DOI: 10.1371/journal.pgen.1000564]
54 Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, Ban HJ, Yoon D, Lee 
MH, Kim DJ, Park M, Cha SH, Kim JW, Han BG, Min H, Ahn Y, 
Park MS, Han HR, Jang HY, Cho EY, Lee JE, Cho NH, Shin C, 
Park T, Park JW, Lee JK, Cardon L, Clarke G, McCarthy MI, Lee 
JY, Lee JK, Oh B, Kim HL. A large-scale genome-wide association 
study of Asian populations uncovers genetic factors influencing 
eight quantitative traits. Nat Genet 2009; 41: 527-534 [PMID: 
19396169 DOI: 10.1038/ng.357]
55 Johnson AD, Newton-Cheh C, Chasman DI, Ehret GB, Johnson 
T, Rose L, Rice K, Verwoert GC, Launer LJ, Gudnason V, Larson 
MG, Chakravarti A, Psaty BM, Caulfield M, van Duijn CM, Ridker 
PM, Munroe PB, Levy D. Association of hypertension drug target 
genes with blood pressure and hypertension in 86,588 individuals. 
Hypertension 2011; 57: 903-910 [PMID: 21444836 DOI: 10.1161/
HYPERTENSIONAHA.110.158667]
Choi MR et al . Renal dopamine: Experimental and clinical evidences
208 May 6, 2015|Volume 4|Issue 2|WJN|www.wjgnet.com
56 Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, 
Glazer NL, Morrison AC, Johnson AD, Aspelund T, Aulchenko Y, 
Lumley T, Köttgen A, Vasan RS, Rivadeneira F, Eiriksdottir G, Guo 
X, Arking DE, Mitchell GF, Mattace-Raso FU, Smith AV, Taylor 
K, Scharpf RB, Hwang SJ, Sijbrands EJ, Bis J, Harris TB, Ganesh 
SK, O’Donnell CJ, Hofman A, Rotter JI, Coresh J, Benjamin EJ, 
Uitterlinden AG, Heiss G, Fox CS, Witteman JC, Boerwinkle E, 
Wang TJ, Gudnason V, Larson MG, Chakravarti A, Psaty BM, van 
Duijn CM. Genome-wide association study of blood pressure and 
hypertension. Nat Genet 2009; 41: 677-687 [PMID: 19430479 DOI: 
10.1038/ng.384]
57 Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, 
Coin L, Najjar SS, Zhao JH, Heath SC, Eyheramendy S, Papadakis 
K, Voight BF, Scott LJ, Zhang F, Farrall M, Tanaka T, Wallace C, 
Chambers JC, Khaw KT, Nilsson P, van der Harst P, Polidoro S, 
Grobbee DE, Onland-Moret NC, Bots ML, Wain LV, Elliott KS, 
Teumer A, Luan J, Lucas G, Kuusisto J, Burton PR, Hadley D, 
McArdle WL, Brown M, Dominiczak A, Newhouse SJ, Samani 
NJ, Webster J, Zeggini E, Beckmann JS, Bergmann S, Lim N, Song 
K, Vollenweider P, Waeber G, Waterworth DM, Yuan X, Groop L, 
Orho-Melander M, Allione A, Di Gregorio A, Guarrera S, Panico S, 
Ricceri F, Romanazzi V, Sacerdote C, Vineis P, Barroso I, Sandhu 
MS, Luben RN, Crawford GJ, Jousilahti P, Perola M, Boehnke M, 
Bonnycastle LL, Collins FS, Jackson AU, Mohlke KL, Stringham 
HM, Valle TT, Willer CJ, Bergman RN, Morken MA, Döring A, 
Gieger C, Illig T, Meitinger T, Org E, Pfeufer A, Wichmann HE, 
Kathiresan S, Marrugat J, O’Donnell CJ, Schwartz SM, Siscovick 
DS, Subirana I, Freimer NB, Hartikainen AL, McCarthy MI, O’
Reilly PF, Peltonen L, Pouta A, de Jong PE, Snieder H, van Gilst 
WH, Clarke R, Goel A, Hamsten A, Peden JF, Seedorf U, Syvänen 
AC, Tognoni G, Lakatta EG, Sanna S, Scheet P, Schlessinger 
D, Scuteri A, Dörr M, Ernst F, Felix SB, Homuth G, Lorbeer R, 
Reffelmann T, Rettig R, Völker U, Galan P, Gut IG, Hercberg S, 
Lathrop GM, Zelenika D, Deloukas P, Soranzo N, Williams FM, 
Zhai G, Salomaa V, Laakso M, Elosua R, Forouhi NG, Völzke H, 
Uiterwaal CS, van der Schouw YT, Numans ME, Matullo G, Navis 
G, Berglund G, Bingham SA, Kooner JS, Connell JM, Bandinelli 
S, Ferrucci L, Watkins H, Spector TD, Tuomilehto J, Altshuler D, 
Strachan DP, Laan M, Meneton P, Wareham NJ, Uda M, Jarvelin 
MR, Mooser V, Melander O, Loos RJ, Elliott P, Abecasis GR, 
Caulfield M, Munroe PB. Genome-wide association study identifies 
eight loci associated with blood pressure. Nat Genet 2009; 41: 
666-676 [PMID: 19430483 DOI: 10.1038/ng.361]
58 Wang Y, O’Connell JR, McArdle PF, Wade JB, Dorff SE, Shah SJ, 
Shi X, Pan L, Rampersaud E, Shen H, Kim JD, Subramanya AR, 
Steinle NI, Parsa A, Ober CC, Welling PA, Chakravarti A, Weder 
AB, Cooper RS, Mitchell BD, Shuldiner AR, Chang YP. From 
the Cover: Whole-genome association study identifies STK39 as 
a hypertension susceptibility gene. Proc Natl Acad Sci USA 2009; 
106: 226-231 [PMID: 19114657 DOI: 10.1073/pnas.0808358106]
59 Moore JH, Williams SM. New strategies for identifying gene-gene 
interactions in hypertension. Ann Med 2002; 34: 88-95 [PMID: 
12108579]
60 Wang X, Villar VA, Armando I, Eisner GM, Felder RA, Jose PA. 
Dopamine, kidney, and hypertension: studies in dopamine receptor 
knockout mice. Pediatr Nephrol 2008; 23: 2131-2146 [PMID: 
18615257 DOI: 10.1007/s00467-008-0901-3]
61 Ohbu K, Kaskel FJ, Kinoshita S, Felder RA. Dopamine-1 receptors 
in the proximal convoluted tubule of Dahl rats: defective coupling 
to adenylate cyclase. Am J Physiol 1995; 268: R231-R235 [PMID: 
7840326]
62 Nishi A, Eklöf AC, Bertorello AM, Aperia A. Dopamine regulation 
of renal Na+,K(+)-ATPase activity is lacking in Dahl salt-sensitive 
rats. Hypertension 1993; 21: 767-771 [PMID: 8099063 DOI: 
10.1161/01.HYP.21.6.767]
63 Iimura O, Ura N, Nakagawa M. Comparative hypertensionology-
renal dopaminergic activity in experimental hypertensive rats. Clin 
Exp Hypertens 1997; 19: 117-130 [PMID: 9028640]
64 Banday AA, Lokhandwala MF. Dopamine receptors and 
hypertension. Curr Hypertens Rep 2008; 10: 268-275 [PMID: 
18625155]
65 Zeng C, Armando I, Luo Y, Eisner GM, Felder RA, Jose PA. 
Dysregulation of dopamine-dependent mechanisms as a determinant 
of hypertension: studies in dopamine receptor knockout mice. 
Am J Physiol Heart Circ Physiol 2008; 294: H551-H569 [PMID: 
18083900]
66 Albrecht FE, Drago J, Felder RA, Printz MP, Eisner GM, Robillard 
JE, Sibley DR, Westphal HJ, Jose PA. Role of the D1A dopamine 
receptor in the pathogenesis of genetic hypertension. J Clin Invest 
1996; 97: 2283-2288 [PMID: 8636408 DOI: 10.1172/JCI118670]
67 Escano CS, Armando I, Wang X, Asico LD, Pascua A, Yang Y, Wang 
Z, Lau YS, Jose PA. Renal dopaminergic defect in C57Bl/6J mice. 
Am J Physiol Regul Integr Comp Physiol 2009; 297: R1660-R1669 
[PMID: 19726707 DOI: 10.1152/ajpregu.00147.2009]
68 Chugh G, Lokhandwala MF, Asghar M. Altered functioning of 
both renal dopamine D1 and angiotensin II type 1 receptors causes 
hypertension in old rats. Hypertension 2012; 59: 1029-1036 [PMID: 
22411927 DOI: 10.1161/HYPERTENSIONAHA.112.192302]
69 Moreira-Rodrigues M, Sampaio-Maia B, Pestana M. Renal 
dopaminergic system activity in rat remnant kidney up to twenty-six 
weeks after surgery. Life Sci 2009; 84: 409-414 [PMID: 19167406 
DOI: 10.1016/j.lfs.2008.12.018]
70 Hussain T, Beheray SA, Lokhandwala MF. Defective dopamine 
receptor function in proximal tubules of obese zucker rats. 
Hypertension 1999; 34: 1091-1096 [PMID: 10567187 DOI: 
10.1161/01.HYP.34.5.1091]
71 Padia SH, Kemp BA, Howell NL, Keller SR, Gildea JJ, Carey RM. 
Mechanisms of dopamine D(1) and angiotensin type 2 receptor 
interaction in natriuresis. Hypertension 2012; 59: 437-445 [PMID: 
22203736 DOI: 10.1161/HYPERTENSIONAHA.111.184788]
72 Salomone LJ, Howell NL, McGrath HE, Kemp BA, Keller SR, 
Gildea JJ, Felder RA, Carey RM. Intrarenal dopamine D1-like 
receptor stimulation induces natriuresis via an angiotensin type-2 
receptor mechanism. Hypertension 2007; 49: 155-161 [PMID: 
17116755 DOI: 10.1161/01.HYP.0000251881.89610.ee]
73 Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable 
cardiovascular risk factor? Hypertension 2005; 46: 454-462 [PMID: 
16103272 DOI: 10.1161/01.HYP.0000177474.06749.98]
74 Pestana M. Hypertension in the elderly. Int Urol Nephrol 2001; 33: 
563-569 [PMID: 12230296]
75 Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’
Agostino RB, Levy D. Residual lifetime risk for developing 
hypertension in middle-aged women and men: The Framingham 
Heart Study. JAMA 2002; 287: 1003-1010 [PMID: 11866648 DOI: 
10.1001/jama.287.8.1003]
76 Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and 
the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 
90: 7915-7922 [PMID: 8367443]
77 Beheray S, Kansra V, Hussain T, Lokhandwala MF. Diminished 
natriuretic response to dopamine in old rats is due to an impaired 
D1-like receptor-signaling pathway. Kidney Int 2000; 58: 712-720 
[PMID: 10916094 DOI: 10.1046/j.1523-1755.2000.00217.x]
78 Zemel MB, Sowers JR. Salt sensitivity and systemic hypertension 
in the elderly. Am J Cardiol 1988; 61: 7H-12H [PMID: 3289354]
79 Baylis C. Renal responses to acute angiotensin II inhibition and 
administered angiotensin II in the aging, conscious, chronically 
catheterized rat. Am J Kidney Dis 1993; 22: 842-850 [PMID: 
8250031]
80 White BH, Sidhu A. Increased oxidative stress in renal proximal 
tubules of the spontaneously hypertensive rat: a mechanism for 
defective dopamine D1A receptor/G-protein coupling. J Hypertens 
1998; 16: 1659-1665 [PMID: 9856367]
81 Becker M, Umrani D, Lokhandwala MF, Hussain T. Increased renal 
angiotensin II AT1 receptor function in obese Zucker rat. Clin Exp 
Hypertens 2003; 25: 35-47 [PMID: 12597523]
82 Banday AA, Marwaha A, Tallam LS, Lokhandwala MF. Tempol 
Choi MR et al . Renal dopamine: Experimental and clinical evidences
209 May 6, 2015|Volume 4|Issue 2|WJN|www.wjgnet.com
reduces oxidative stress, improves insulin sensitivity, decreases 
renal dopamine D1 receptor hyperphosphorylation, and restores 
D1 receptor-G-protein coupling and function in obese Zucker rats. 
Diabetes 2005; 54: 2219-2226 [PMID: 15983225 DOI: 10.2337/
diabetes.54.7.2219]
83 Javkhedkar AA, Lokhandwala MF, Banday AA. Higher renal AT1 
receptor affinity exaggerates Ang II induced Na/K-ATPase stimulation 
in spontaneously hypertensive rats. FASEB J 2010; 24: 707
84 Zhang Y, Fu C, Ren H, He D, Wang X, Asico LD, Jose PA, Zeng 
C. Impaired stimulatory effect of ETB receptor on D receptor 
in immortalized renal proximal tubule cells of spontaneously 
hypertensive rats. Kidney Blood Press Res 2011; 34: 75-82 [PMID: 
21228598 DOI: 10.1159/000323135]
85 Zeng C, Asico LD, Yu C, Villar VA, Shi W, Luo Y, Wang Z, He 
D, Liu Y, Huang L, Yang C, Wang X, Hopfer U, Eisner GM, Jose 
PA. Renal D3 dopamine receptor stimulation induces natriuresis by 
endothelin B receptor interactions. Kidney Int 2008; 74: 750-759 
[PMID: 18547994 DOI: 10.1038/ki.2008.247]
86 Yu C, Yang Z, Ren H, Zhang Y, Han Y, He D, Lu Q, Wang X, Wang 
X, Yang C, Asico LD, Hopfer U, Eisner GM, Jose PA, Zeng C. D3 
dopamine receptor regulation of ETB receptors in renal proximal 
tubule cells from WKY and SHRs. Am J Hypertens 2009; 22: 
877-883 [PMID: 19390510 DOI: 10.1038/ajh.2009.80]
87 Fernandez MM, Gonzalez D, Williams JM, Roman RJ, Nowicki S. 
Inhibitors of 20-hydroxyeicosatetraenoic acid (20-HETE) formation 
attenuate the natriuretic effect of dopamine. Eur J Pharmacol 2012; 
686: 97-103 [PMID: 22575524 DOI: 10.1016/j.ejphar.2012.04.039]
88 Kirchheimer C, Mendez CF, Acquier A, Nowicki S. Role of 
20-HETE in D1/D2 dopamine receptor synergism resulting in the 
inhibition of Na+-K+-ATPase activity in the proximal tubule. Am J 
Physiol Renal Physiol 2007; 292: F1435-F1442 [PMID: 17264308 
DOI: 10.1152/ajprenal.00176.2006]
89 Maier KG, Roman RJ. Cytochrome P450 metabolites of 
arachidonic acid in the control of renal function. Curr Opin Nephrol 
Hypertens 2001; 10: 81-87 [PMID: 11195057 DOI: 10.1042/
CS20110215]
90 Schlaich M, Socratous F, Eikelis N. Renalase plasma levels are 
associated with systolic blood pressure in patients with resistant 
hypertension: 9C.01. J Hypertens 2010; 28: 437 [DOI: 10.1097/01.
hjh.0000379519.82971.02]
91 Desir GV, Wu Y, Wang P. Renalase deficiency increases sympathetic 
tone and causes hypertension. J Am Soc Nephrol 2008. Available 
from: URL: http: //www.asn-online.org/education_and_meetings/
renal_week/archives/
92 Pestana M, Sampaio-Maia B, Moreira-Rodrigues M. Expression of 
renalase in a 3/4 nephrectomy rat model. NDT Plus 2009; 2: 55
93 Desir G, Tang L, Wang P, Li G, Velazquez H. Antihypertensive 
effect of recombinant renalase in Dahl salt sensitive (DSS) 
rats. 2010. Available from: URL:  http: //www.asn-online.org/
education_and_meetings/renal_week/archives/
94 US Renal Data System. USRDS 2008 Annual Data Report: 
Atlas of Chronic Kidney Disease and End-Stage Renal Disease 
in the United States. Bethesda, MD: National Institutes of Health, 
National Institute of Diabetes and Digestive and Kidney Diseases, 
2008
95 Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. 
Glomerular hyperfiltration in experimental diabetes mellitus: 
potential role of tubular reabsorption. J Am Soc Nephrol 1999; 10: 
2569-2576 [PMID: 10589696]
96 Thomson SC, Vallon V, Blantz RC. Kidney function in early 
diabetes: the tubular hypothesis of glomerular filtration. Am J 
Physiol Renal Physiol 2004; 286: F8-15 [PMID: 14656757 DOI: 
10.1152/ajprenal.00208.2003]
97 Bjornstad P, Maahs DM, Cherney DZ, Cree-Green M, West A, 
Pyle L, Nadeau KJ. Insulin sensitivity is an important determinant 
of renal health in adolescents with type 2 diabetes. Diabetes Care 
2014; 37: 3033-3039 [PMID: 25071077]
98 Bjornstad P, Snell-Bergeon JK, Rewers M, Jalal D, Chonchol MB, 
Johnson RJ, Maahs DM. Early diabetic nephropathy: a complication 
of reduced insulin sensitivity in type 1 diabetes. Diabetes Care 
2013; 36: 3678-3683 [PMID: 24026551 DOI: 10.2337/dc13-0631]
99 Brosius FC, Alpers CE. New targets for treatment of diabetic 
nephropathy: what we have learned from animal models. Curr 
Opin Nephrol Hypertens 2013; 22: 17-25 [PMID: 23207723 DOI: 
10.1097/MNH.0b013e32835b3766]
100 Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclo-
oxygenase-2 inhibition attenuates the progression of nephropathy in 
uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 2007; 
34: 36-41 [PMID: 17201733 DOI: 10.1111/j.1440-1681.2007.04534.x]
101 Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader 
SL, Anderson S. Immunohistochemical and functional correlations 
of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 
2001; 107: 889-898 [PMID: 11285308 DOI: 10.1172/JCI10228]
102 Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, 
Harris RC. Cyclooxygenase-2 inhibitor blocks expression of 
mediators of renal injury in a model of diabetes and hypertension. 
Kidney Int 2002; 62: 929-939 [PMID: 12164875 DOI: 10.1046/
j.1523-1755.2002.00520.x]
103 Carranza A, Karabatas L, Barontini M, Armando I. Decreased 
tubular uptake of L-3,4-dihydroxyphenylalanine in streptozotocin-
induced diabetic rats. Horm Res 2001; 55: 282-287 [PMID: 
11805432]
104 Marwaha A, Banday AA, Lokhandwala MF. Reduced renal 
dopamine D1 receptor function in streptozotocin-induced diabetic 
rats. Am J Physiol Renal Physiol 2004; 286: F451-F457 [PMID: 
14612382 DOI: 10.1152/ajprenal.00227.2003]
105 Carranza A, Musolino PL, Villar M, Nowicki S. Signaling cascade 
of insulin-induced stimulation of L-dopa uptake in renal proximal 
tubule cells. Am J Physiol Cell Physiol 2008; 295: C1602-C1609 
[PMID: 18842830 DOI: 10.1152/ajpcell.00090.2008]
106 Tsuchida H, Imai G, Shima Y, Satoh T, Owada S. Mechanism 
of sodium load-induced hypertension in non-insulin dependent 
diabetes mellitus model rats: defective dopaminergic system to 
inhibit Na-K-ATPase activity in renal epithelial cells. Hypertens Res 
2001; 24: 127-135 [PMID: 11325071 DOI: 10.1291/hypres.24.127]
107 Umrani DN , Banday AA, Hussain T, Lokhandwala MF. 
Rosiglitazone treatment restores renal dopamine receptor function 
in obese Zucker rats. Hypertension 2002; 40: 880-885 [PMID: 
12468573 DOI: 10.1161/01.HYP.0000039963.01288.D3]
108 Trivedi M, Lokhandwala MF. Rosiglitazone restores renal 
D1A receptor-Gs protein coupling by reducing receptor hyperp-
hosphorylation in obese rats. Am J Physiol Renal Physiol 2005; 289: 
F298-F304 [PMID: 15798088 DOI: 10.1152/ajprenal.00362.2004]
109 Kuzhikandathil EV, Clark L, Li Y. The extracellular cAMP-
adenosine pathway regulates expression of renal D1 dopamine 
receptors in diabetic rats. J Biol Chem 2011; 286: 32454-32463 
[PMID: 21803776 DOI: 10.1074/jbc.M111.268136]
110 Barthelmebs M, Mayer P, Thomas A, Grima M, Imbs JL. 
Pathophysiological role of dopamine in the kidney: effects in 
diabetes mellitus and after contralateral nephrectomy. Hypertens 
Res 1995; 18 Suppl 1: S131-S136 [PMID: 8529042 DOI: 10.1291/
hypres.18.SupplementI_S131]
111 Luippold G, Beilharz M, Mühlbauer B. Reduction of glomerular 
hyperfiltration by dopamine D(2)-like receptor blockade in 
experimental diabetes mellitus. Nephrol Dial Transplant 2001; 16: 
1350-1356 [PMID: 11427624 DOI: 10.1093/ndt/16.7.1350]
112 Luippold G, Schneider S, Vallon V, Osswald H, Mühlbauer 
B. Postglomerular vasoconstriction induced by dopamine D(3) 
receptor activation in anesthetized rats. Am J Physiol Renal Physiol 
2000; 278: F570-F575 [PMID: 10751217]
113 Gross ML, Koch A, Mühlbauer B, Adamczak M, Ziebart H, 
Drescher K, Gross G, Berger I, Amann KU, Ritz E. Renoprotective 
effect of a dopamine D3 receptor antagonist in experimental type 
II diabetes. Lab Invest 2006; 86: 262-274 [PMID: 16402031 DOI: 
10.1038/labinvest.3700383]
114 Chamorro C, Romera MA, Martinez-Melgar JL, Pardo C, Silva JA. 
Choi MR et al . Renal dopamine: Experimental and clinical evidences
210 May 6, 2015|Volume 4|Issue 2|WJN|www.wjgnet.com
Dopamine dose and renal damage. Lancet 2001; 357: 1707-1708 
[PMID: 11428365 DOI: 10.1016/S0140-6736(00)04838-8]
115 Lee MR. Dopamine and the kidney: ten years on. Clin Sci (Lond) 
1993; 84: 357-375 [PMID: 8482041]
116 Mcdonald RH, Goldberg LI, Mcnay JL, Tuttle EP. Effect of 
dopamine in man: augmentation of sodium excretion, glomerular 
filtration rate, and renal plasma flow. J Clin Invest 1964; 43: 
1116-1124 [PMID: 14171789]
117 Hollenberg NK, Adams DF, Mendell P, Abrams HL, Merrill 
JP. Renal vascular responses to dopamine: haemodynamic and 
angiographic observations in normal man. Clin Sci Mol Med 1973; 
45: 733-742 [PMID: 4760032]
118 Cuthbertson BH, Noble DW. Dopamine in oliguria. BMJ 1997; 
314: 690-691 [PMID: 9116537]
119 Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. 
Low-dose dopamine in patients with early renal dysfunction: 
a placebo-controlled randomised trial. Australian and New 
Zealand Intensive Care Society (ANZICS) Clinical Trials Group. 
Lancet 2000; 356: 2139-2143 [PMID: 11191541 DOI: 10.1016/
S0140-6736(00)03495-4]
120 Kellum JA, M Decker J. Use of dopamine in acute renal failure: 
a meta-analysis. Crit Care Med 2001; 29: 1526-1531 [PMID: 
11505120]
121 Marik PE. Low-dose dopamine: a systematic review. Intensive 
Care Med 2002; 28: 877-883 [PMID: 12122525]
122 Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri 
VM, De Backer D, Payen D. Does dopamine administration in 
shock influence outcome? Results of the Sepsis Occurrence in 
Acutely Ill Patients (SOAP) Study. Crit Care Med 2006; 34: 
589-597 [PMID: 16505643]
123 Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran 
MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, 
Konstam MA, Huggins GS, Rouleau JL, O’Meara E, Tang WH, 
Starling RC, Butler J, Deswal A, Felker GM, O’Connor CM, Bonita 
RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román 
VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, 
Hernandez AF, Braunwald E, Redfield MM. Low-dose dopamine 
or low-dose nesiritide in acute heart failure with renal dysfunction: 
the ROSE acute heart failure randomized trial. JAMA 2013; 310: 
2533-2543 [PMID: 24247300 DOI: 10.1001/jama.2013.282190]
124 Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis 
C, Rovithis D, Economou D, Savvatis K, Kirlidis T, Tsaknakis T, 
Skoularigis J, Westermann D, Tschöpe C, Triposkiadis F. Impact 
of dopamine infusion on renal function in hospitalized heart failure 
patients: results of the Dopamine in Acute Decompensated Heart 
Failure (DAD-HF) Trial. J Card Fail 2010; 16: 922-930 [PMID: 
21111980 DOI: 10.1016/j.cardfail.2010.07.246]
125 Aziz EF, Alviar CL, Herzog E, Cordova JP, Bastawrose 
JH, Pamidimukala CK, Tojino A, Park TS, Musat D, Kukin 
M. Continuous infusion of furosemide combined with low-
dose dopamine compared to intermittent boluses in acutely 
decompensated heart failure is less nephrotoxic and carries a lower 
readmission at thirty days. Hellenic J Cardiol 2011; 52: 227-235 
[PMID: 21642071]
126 Ricci Z, Luciano R, Favia I, Garisto C, Muraca M, Morelli S, 
Di Chiara L, Cogo P, Picardo S. High-dose fenoldopam reduces 
postoperative neutrophil gelatinase-associated lipocaline and 
cystatin C levels in pediatric cardiac surgery. Crit Care 2011; 15: 
R160 [PMID: 21714857 DOI: 10.1186/cc10295]
127 Kamiya M, Sato N, Akiya M, Okazaki H, Takahashi Y, Mizuno 
K. A case of marked diuresis by combined dopamine and atrial 
natriuretic peptide administration without renal injury in acute 
decompensated heart failure. Int Heart J 2013; 54: 243-245 [PMID: 
23924940 DOI: 10.1536/ihj.54.243]
128 Sumeray M, Robertson C, Lapsley M, Bomanji J, Norman AG, 
Woolfson RG. Low dose dopamine infusion reduces renal tubular 
injury following cardiopulmonary bypass surgery. J Nephrol 2001; 
14: 397-402 [PMID: 11730274]
129 Kim CS. Pharmacologic Management of the Cardio-renal 
Syndrome. Electrolyte Blood Press 2013; 11: 17-23 [PMID: 
23946761 DOI: 10.5049/EBP.2013.11.1.17]
130 Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, 
Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, 
de Zeeuw D, Pocock S, van Veldhuisen DJ. Renal function as a 
predictor of outcome in a broad spectrum of patients with heart 
failure. Circulation 2006; 113: 671-678 [PMID: 16461840]
131 Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. 
The severe cardiorenal syndrome: ‘Guyton revisited’. Eur Heart J 
2005; 26: 11-17 [PMID: 15615794]
132 Koniari K, Parissis J, Paraskevaidis I, Anastasiou-Nana M. 
Treating volume overload in acutely decompensated heart failure: 
established and novel therapeutic approaches. Eur Heart J Acute 
Cardiovasc Care 2012; 1: 256-268 [PMID: 24062916 DOI: 10.117
7/2048872612457044]
133 Zappitelli M, Bernier PL, Saczkowski RS, Tchervenkov CI, 
Gottesman R, Dancea A, Hyder A, Alkandari O. A small post-
operative rise in serum creatinine predicts acute kidney injury in 
children undergoing cardiac surgery. Kidney Int 2009; 76: 885-892 
[PMID: 19641482 DOI: 10.1038/ki.2009.270]
134 Picca S, Ricci Z, Picardo S. Acute kidney injury in an infant after 
cardiopulmonary bypass. Semin Nephrol 2008; 28: 470-476 [PMID: 
18790366 DOI: 10.1016/j.semnephrol.2008.05.006]
135 van der Vorst MM, Ruys-Dudok van Heel I, Kist-van Holthe JE, 
den Hartigh J, Schoemaker RC, Cohen AF, Burggraaf J. Continuous 
intravenous furosemide in haemodynamically unstable children 
after cardiac surgery. Intensive Care Med 2001; 27: 711-715 [PMID: 
11398698]
136 Tumlin JA. Impaired blood flow in acute kidney injury: 
pathophysiology and potential efficacy of intrarenal vasodilator 
therapy. Curr Opin Crit Care 2009; 15: 514-519 [PMID: 19829105 
DOI: 10.1097/MCC.0b013e328332f6f9]
137 Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, 
Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling 
RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 
Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 
16: e1-194 [PMID: 20610207 DOI: 10.1016/j.cardfail.2010.04.004]
138 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner 
MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson 
MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray 
JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, 
Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the 
management of heart failure: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on 
Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239 [PMID: 
23747642 DOI: 10.1161/CIR.0b013e31829e8776]
139 Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, 
Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, 
Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel 
A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw 
A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P. 
Cardio-renal syndromes: report from the consensus conference of 
the acute dialysis quality initiative. Eur Heart J 2010; 31: 703-711 
[PMID: 20037146 DOI: 10.1093/eurheartj/ehp507]
140 Fernández BE, Correa AH, Choi MR. Atrial natriuretic factor 
stimulates renal dopamine uptake mediated by natriuretic peptide-
type A receptor. Regul Pept 2005; 124: 137-144 [PMID: 15544851]
141 Correa AH, Choi MR, Gironacci M, Aprile F, Fernández BE. Atrial 
natriuretic factor decreases renal dopamine turnover and catabolism 
without modifying its release. Regul Pept 2008; 146: 238-242 
[PMID: 17963868]
142 Humphreys MH. Mechanisms and management of nephrotic 
edema. Kidney Int 1994; 45: 266-281 [PMID: 8127018]
143 Deschênes G, Wittner M, Stefano A, Jounier S, Doucet A. 
Collecting duct is a site of sodium retention in PAN nephrosis: 
a rationale for amiloride therapy. J Am Soc Nephrol 2001; 12: 
598-601 [PMID: 11181809]
Choi MR et al . Renal dopamine: Experimental and clinical evidences
211 May 6, 2015|Volume 4|Issue 2|WJN|www.wjgnet.com
144 Sampaio-Maia B, Moreira-Rodrigues M, Serrão P, Pestana 
M. Blunted renal dopaminergic system activity in puromycin 
aminonucleoside-induced nephrotic syndrome. Nephrol Dial 
Transplant 2006; 21: 314-323 [PMID: 16204272]
145 Marin-Grez M, Briggs JP, Schubert G, Schnermann J. Dopamine 
receptor antagonists inhibit the natriuretic response to atrial natriuretic 
factor (ANF). Life Sci 1985; 36: 2171-2176 [PMID: 3158789]
146 Trivedi M, Narkar VA, Hussain T, Lokhandwala MF. Dopamine 
recruits D1A receptors to Na-K-ATPase-rich caveolar plasma 
membranes in rat renal proximal tubules. Am J Physiol Renal 
Physiol 2004; 287: F921-F931 [PMID: 15265765]
147 Fernandes-Cerqueira C, Sampaio-Maia B, Quelhas-Santos J, 
Moreira-Rodrigues M, Simões-Silva L, Blazquez-Medela AM, 
Martinez-Salgado C, Lopez-Novoa JM, Pestana M. Concerted 
action of ANP and dopamine D1-receptor to regulate sodium 
homeostasis in nephrotic syndrome. Biomed Res Int 2013; 2013: 
397391 [PMID: 23956981 DOI: 10.1155/2013/397391]
148 Vohra PK, Hoeppner LH, Sagar G, Dutta SK, Misra S, Hubmayr 
RD, Mukhopadhyay D. Dopamine inhibits pulmonary edema 
through the VEGF-VEGFR2 axis in a murine model of acute lung 
injury. Am J Physiol Lung Cell Mol Physiol 2012; 302: L185-L192 
[PMID: 22003095 DOI: 10.1152/ajplung.00274.2010]
149 Adir Y, Sznajder JI. Regulation of lung edema clearance by 
dopamine. Isr Med Assoc J 2003; 5: 47-50 [PMID: 12592959]
150 Ware LB, Matthay MA. The acute respiratory distress syndrome. 
N Engl J Med 2000; 342: 1334-1349 [PMID: 10793167 DOI: 
10.1056/NEJM200005043421806]
151 Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the 
majority of patients with acute lung injury and the acute respiratory 
distress syndrome. Am J Respir Crit Care Med 2001; 163: 
1376-1383 [PMID: 11371404 DOI: 10.1164/ajrccm.163.6.2004035]
152 Sznajder JI. Strategies to increase alveolar epithelial fluid 
removal in the injured lung. Am J Respir Crit Care Med 1999; 160: 
1441-1442 [PMID: 10556102]
153 Dematte JE, Sznajder JI. Mechanisms of pulmonary edema 
clearance: from basic research to clinical implication. Intensive 
Care Med 2000; 26: 477-480 [PMID: 10872144]
154 Goldberg LI. Cardiovascular and renal actions of dopamine: 
potential clinical applications. Pharmacol Rev 1972; 24: 1-29 
[PMID: 4554480]
155 McGrath B, Bode K, Luxford A, Howden B, Jablonski P. Effects 
of dopamine on renal function in the rat isolated perfused kidney. 
Clin Exp Pharmacol Physiol 1985; 12: 343-352 [PMID: 3912084]
156 Barnard ML, Ridge KM, Saldias F, Friedman E, Gare M, Guerrero 
C, Lecuona E, Bertorello AM, Katz AI, Sznajder JI. Stimulation 
of the dopamine 1 receptor increases lung edema clearance. Am J 
Respir Crit Care Med 1999; 160: 982-986 [PMID: 10471628 DOI: 
10.1164/ajrccm.160.3.9812003]
157 Ridge KM, Dada L, Lecuona E, Bertorello AM, Katz AI, Mochly-
Rosen D, Sznajder JI. Dopamine-induced exocytosis of Na,K-
ATPase is dependent on activation of protein kinase C-epsilon and 
-delta. Mol Biol Cell 2002; 13: 1381-1389 [PMID: 11950946 DOI: 
10.1091/mbc.01-07-0323]
158 Lecuona E, Garcia A, Sznajder JI. A novel role for protein 
phosphatase 2A in the dopaminergic regulation of Na,K-ATPase. 
FEBS Lett 2000; 481: 217-220 [PMID: 11007967 DOI: 10.1016/
S0014-5793(00)02009-3]
159 Bertorello AM, Sznajder JI. The dopamine paradox in lung and 
kidney epithelia: sharing the same target but operating different 
signaling networks. Am J Respir Cell Mol Biol 2005; 33: 432-437 
[PMID: 16234332 DOI: 10.1165/rcmb.2005-0297TR]
160 Guerrero C, Lecuona E, Pesce L, Ridge KM, Sznajder JI. Dopamine 
regulates Na-K-ATPase in alveolar epithelial cells via MAPK-ERK-
dependent mechanisms. Am J Physiol Lung Cell Mol Physiol 2001; 
281: L79-L85 [PMID: 11404249]
161 Leaver SK, Evans TW. Acute respiratory distress syndrome. BMJ 2007; 
335: 389-394 [PMID: 17717368 DOI: 10.1136/bmj.39293.624699.AD]
162 Matthay MA, Calfee CS. Therapeutic value of a lung protective 
ventilation strategy in acute lung injury. Chest 2005; 128: 
3089-3091 [PMID: 16304246 DOI: 10.1378/chest.128.5.3089]
163 Ware LB, Kaner RJ, Crystal RG, Schane R, Trivedi NN, McAuley 
D, Matthay MA. VEGF levels in the alveolar compartment do not 
distinguish between ARDS and hydrostatic pulmonary oedema. Eur 
Respir J 2005; 26: 101-105 [PMID: 15994395 DOI: 0.1183/090319
36.05.00106604]
164 Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory 
distress syndrome: a clinical review. Lancet 2007; 369: 1553-1564 
[PMID: 17482987 DOI: 10.1016/S0140-6736(07)60604-7]
165 Becker PM, Alcasabas A, Yu AY, Semenza GL, Bunton TE. 
Oxygen-independent upregulation of vascular endothelial growth 
factor and vascular barrier dysfunction during ventilated pulmonary 
ischemia in isolated ferret lungs. Am J Respir Cell Mol Biol 2000; 
22: 272-279 [PMID: 10696063 DOI: 10.1165/ajrcmb.22.3.3814]
166 Bhandari V, Choo-Wing R, Lee CG, Yusuf K, Nedrelow JH, 
Ambalavanan N, Malkus H, Homer RJ, Elias JA. Developmental 
regulation of NO-mediated VEGF-induced effects in the lung. Am 
J Respir Cell Mol Biol 2008; 39: 420-430 [PMID: 18441284 DOI: 
10.1165/rcmb.2007-0024OC]
167 Godzich M, Hodnett M, Frank JA, Su G, Pespeni M, Angel A, 
Howard MB, Matthay MA, Pittet JF. Activation of the stress 
protein response prevents the development of pulmonary edema 
by inhibiting VEGF cell signaling in a model of lung ischemia-
reperfusion injury in rats. FASEB J 2006; 20: 1519-1521 [PMID: 
16793871 DOI: 10.1096/fj.05-4708fje]
168 Gurkan OU, O’Donnell C, Brower R, Ruckdeschel E, Becker PM. 
Differential effects of mechanical ventilatory strategy on lung injury 
and systemic organ inflammation in mice. Am J Physiol Lung Cell 
Mol Physiol 2003; 285: L710-L718 [PMID: 12754185 DOI: 0.1152/
ajplung.00044.2003]
169 Kaner RJ, Crystal RG. Pathogenesis of high altitude pulmonary 
edema: does alveolar epithelial lining fluid vascular endothelial 
growth factor exacerbate capillary leak? High Alt Med Biol 2004; 5: 
399-409 [PMID: 15671629 DOI: 10.1089/ham.2004.5.399]
170 Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, 
Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The 
neurotransmitter dopamine inhibits angiogenesis induced by 
vascular permeability factor/vascular endothelial growth factor. Nat 
Med 2001; 7: 569-574 [PMID: 11329058 DOI: 10.1038/87895]
171 Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta 
PS, Basu S. Depleted dopamine in gastric cancer tissues: 
dopamine treatment retards growth of gastric cancer by inhibiting 
angiogenesis. Clin Cancer Res 2004; 10: 4349-4356 [PMID: 
15240521 DOI: 10.1158/1078-0432.CCR-04-0059]
172 Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, 
Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation 
of VEGFR-2, MAPK, and focal adhesion kinase in endothelial 
cells. Am J Physiol Heart Circ Physiol 2004; 287: H1554-H1560 
[PMID: 15371263 DOI: 10.1152/ajpheart.00272.2004]
173 Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, 
double-blind, placebo-controlled trial of pramipexole added to 
mood stabilizers for treatment-resistant bipolar depression. Am J 
Psychiatry 2004; 161: 564-566 [PMID: 14992985 DOI: 10.1176/
appi.ajp.161.3.564]
174 Kleiner-Fisman G, Fisman DN. Risk factors for the development of 
pedal edema in patients using pramipexole. Arch Neurol 2007; 64: 
820-824 [PMID: 17420306 DOI: 10.1001/archneur.64.6.noc60158]
175 Tan EK, Ondo W. Clinical characteristics of pramipexole-
induced peripheral edema. Arch Neurol 2000; 57: 729-732 [PMID: 
10815140 DOI: 10.1001/archneur.57.5.729]
176 Sato S, Hori T, Tsutsumi K, Asada T. Pramipexole-induced peripheral 
edema in a patient with bipolar depression. J Neuropsychiatry Clin 
Neurosci 2011; 23: E20 [PMID: 22231331 DOI: 10.1176/appi.
neuropsych.23.4.e20]
177 Biglan KM, Holloway RG, McDermott MP, Richard IH. Risk 
factors for somnolence, edema, and hallucinations in early 
Parkinson disease. Neurology 2007; 69: 187-195 [PMID: 17620552]
178 Zavala JA, Munhoz RP, Teive HA. Pramipexole-related chronic 
lower limb oedema in a patient with Parkinson’s disease. J Clin 
Neurosci 2012; 19: 1298-1299 [PMID: 22721884 DOI: 10.1016/
Choi MR et al . Renal dopamine: Experimental and clinical evidences
212 May 6, 2015|Volume 4|Issue 2|WJN|www.wjgnet.com
j.jocn.2011.12.011]
179 Aperia AC. Intrarenal dopamine: a key signal in the interactive 
regulation of sodium metabolism. Annu Rev Physiol 2000; 62: 
621-647 [PMID: 10845105]
P- Reviewer: Bjornstad P,  Nihalani D, Riutta A 
S- Editor: Song XX    L- Editor: A    E- Editor: Lu YJ
Choi MR et al . Renal dopamine: Experimental and clinical evidences
© 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
